Onco Wiki / Droga

Carboplatin

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDDRUG-CARBOPLATIN
TipoFármaco
Alegais
ParaplatinaКарбоплатин
Estadoreviewed 2026-04-26 | pending_clinical_signoff
DoençasDIS-ANAL-SCC DIS-BREAST DIS-BURKITT DIS-CERVICAL DIS-EATL DIS-ENDOMETRIAL DIS-ESOPHAGEAL DIS-GRANULOSA-CELL DIS-HNSCC DIS-HSTCL DIS-LARYNGEAL DIS-NSCLC DIS-OVARIAN DIS-PMBCL DIS-SALIVARY DIS-SCLC DIS-THYROID-ANAPLASTIC DIS-UROTHELIAL
FontesSRC-NCCN-BCELL-2025 SRC-NCCN-ESOPHAGEAL-2025

Fatos sobre as drogas

ClasseAgente alquilante de platina (de segunda geração)
MecanismoCisplatin analog with a cyclobutane-dicarboxylate leaving group that hydrolyzes more slowly than cisplatin's chloride ligands → slower formation of activated aquated species, lower reactivity with plasma proteins, and lower nephrotoxicity / ototoxicity / neurotoxicity. The same DNA platinum-adduct biology drives cytotoxicity. Dose individualized by Calvert formula because clearance is dominated by glomerular filtration. Myelosuppression — particularly thrombocytopenia — is the dose-limiting toxicity.
Dose típicaFórmula de calver: dose (mg) = AUC × (GFR + 25). Tampa de GFR a 125 ml/min recomendada (FDA 2010) quando medida por Cockcroft- Gault para evitar sobredosagem em doentes com GFR superestimada. Ovarian 1L (carbo/paclitaxel): AUC 5-6 IV q21d × 6 ciclos. NSCLC (carba/pallitaxel): AUC 6 IV q 21d × 4-6 ciclos . CROSS (TC esofágica): ASC 2 IV × 5 semanalmente com paclitagel 50 mg/m2. ICE (recuperação de linfoma): ACC 5 (max 800 mg) IV dia 2. PIB, gem-carbo: ASC 4-5 IV q21)d. TNBC neoadjuvante (adicionado a AC-T ou KEYNOTE-522): AUC 1,5 semanal ou AUC 5 q21d com paclitaxel. AUC inferior (3-4) para idosos / frágeis / fortemente pré-tratados.
Ucrânia registadaVerdade
NSZU reembolsadoVerdade
Ucrânia verificada pela última vez2026-04-27

Avisos

Notas

Calvert AUC dose calculation requires GFR (Cockcroft-Gault, CKD-EPI, or measured); engine uses creatinine_clearance_ml_min finding for AUC computation. CAP at 125 mL/min per FDA 2010 to prevent overdose. Hypersensitivity prevention: gradual desensitization protocols available for re-exposure beyond cycle 6. Less hydration required than cisplatin (no mandatory pre/post hydration regimen). Platelet nadir day 14-21 — schedule q21d to allow recovery. Monitor CBC weekly for first 4 cycles.

Usado por

Indicação

Esquema terapêutico